Want to join the conversation?
$ABBV 2Q15 10-Q: On May 26, 2015, ABBV acquired Pharmacyclics through a tender offer for approx. $20.8Bil, including cash consideration of $12.4Bil and equity consideration of $8.4Bil. ABBV entered into and executed a $5Bil ASR agreement with Morgan Stanley on May 26, 2015, pursuant to which ABBV paid $5Bil for initial delivery of 68MM shares.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.